

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SoftMedx Healthcare Limited

京玖醫療健康有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the annual report and interim report of SoftMedx Healthcare Limited (the “Company”, together with its subsidiaries, the “Group”) for the year ended 31 December 2023 and the six months ended 30 June 2024 respectively.

The Company supplements that as at 31 December 2023 and 30 June 2024, the Group’s financial asset at fair value through profit or loss (“Financial Asset”) comprised 5,290,564 shares of Alman Limited (stock code: 08186, representing 4.6% of the issued shares of this investee company) with investment cost of HK\$1.2 million. For the year ended 31 December 2023 and the six months ended 30 June 2024, the Group did not receive dividend from the Financial Asset and recorded unrealised gain of HK\$15.1 million and unrealised loss of HK\$5.4 million respectively. As at 31 December 2023 and 30 June 2024, the fair value of the Financial Asset amounted to HK\$20.5 million and HK\$5.4 million, representing 36.6% and 10.8% of the Group’s total assets respectively.

The investee company is principally engaged in the household, plantation and accessory businesses. The Company noted that the investee has significantly improved its financial position in the past year and the Company is optimistic about the growth and performance of the investee company in the upcoming years. Having said that, the Company acknowledges that the future performance of the Financial Asset will be affected by the fundamentals of the investee company, the economic conditions and investors’ sentiment in Hong Kong. The objective and investment strategy of the Company’s holding of the Financial Asset was for obtaining capital gain as a long-term investment and for risk diversification.

Trading in the shares of the Company will continue to be suspended pending fulfilment of the resumption conditions. Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company

For and on behalf of the board of
SoftMedx Healthcare Limited
Lam Sung Him Gaston
Company Secretary

Hong Kong, 5 September 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Lin Pinzhao as executive director; and Mr. Ngok Ho Wai, Ms. Tang Cuihuen and Mr. Yiu Chun Wing as independent non-executive directors.